Volume 2007, Issue 2

Abstract

Colorectal cancer (CRC) is one of the most frequent and aggressive neoplasms. It is the second leading cause of death from cancer in the United States and is a significant overall health problem. Tumor markers are substances synthesized and excreted by tumor tissues that can be detected in abnormal concentrations in serum, urine, and other body fluids. Two such markers, Carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA 19-9), are useful in the diagnosis, prognosis and management of colorectal carcinoma. This study attempted to evaluate the clinical and prognostic value of the two markers using forty patients with CRC and ten healthy persons as a control group. All patients with CRC showed highly significant increases in CEA and CA-19-9 compared to the control group (p <  0.001), and there was a highly significant increase in the level of CEA in more advanced tumor stages, (p <  0.01). Regression analysis showed a significant correlation between CEA and CA-19-9 (p <  0.05; r = 0.35) and significant increases in CEA in rectal tumors compared to those located in the colon; in males compared to females (p <  0.05); and also a highly significant increase in patients over 60 years of age (p < 0.01) but no relation between CA 19-9 level and age, sex, and site of tumor. These data suggest that serum levels of CEA and CA-19-9 can be clinically useful in the diagnosis and staging of colorectal carcinoma.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2007.2.8
2007-11-01
2024-03-29
Loading full text...

Full text loading...

References

  1. De Cosse JJ, Tasiolias GJ, Jacob son JS. Colorectal Cancer 1 detection, treatment and rehabilitation. Cancer- Cancer J Clin. 1994; 44::2742.
    [Google Scholar]
  2. Knopf KB, Warren JI, Feuer EJ, Brown ML. Bowel surveillance pattern after a diagnosis of colorectal cancer in Medicare beneficiaries. American Society for Gastroenterology endoscopy. 2001; 54:5.
    [Google Scholar]
  3. Thomas WM, Robertson JFR, Hardcastle JD. Failure of CA 19-9 to detect asymptomatic colorectal carcinoma. Br. J. Cancer. 1991; 63::975976.
    [Google Scholar]
  4. Reiter W, stieber P, Renter C, et al., Multivariate analysis of prognostic value of CEA and CA 19-9 serum levels in colorectal carcinoma. Anticancer Res Dec. 2000; 20:61:51955198.
    [Google Scholar]
  5. Kim FC, Rob SA, Kim HC, Koo KH, Cob YK, et al., Co-expression of Carcinoembryonic Antigen and E-cadherin in Colorectal Adeno-carcinoma with liver metastasis. Gastrointestinal Surg. 2003; 7::931938.
    [Google Scholar]
  6. Dixon MR, Haukoos JS, Udani SM, Naghi JJ, et al., Carcinoembryonic Antigen and Albumin Predict Survival in Patients With Advanced Colon and Rectal Cancer. Arch Surg. 2003; 138::962966.
    [Google Scholar]
  7. Shimono R, Mori M, Akazawak K, et al., Immunohistochemical Expression of carbohydrate antigen 19-9 in colorectal carcinoma. American J of Gastroenterology. 1994; 89:1:101105.
    [Google Scholar]
  8. Mroczko B, Szmitkowski M, Okulczy k, et al., Hematopoitic Growth Factor in Colorectal Cancer Patients. Clin Chem. Lab Med. 2003; 5:41:646651.
    [Google Scholar]
  9. Kuo LJ, Leu SY, Liu MC, et al., How aggressive should we be in patients with Stage IV colorectal carcinoma ? Dis Colon. Rectum, Dec. 2003; 46::16461652.
    [Google Scholar]
  10. Yukawa N, Yoshikawa T, Akaike M, et al., Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma. Br. J. of Surgery. 2001; 88::15961601.
    [Google Scholar]
  11. Horie Y, Miura K, Mastui K, et al., Marked elevation of plasma CEA and stomach cancer. Cancer. 1996; 77::19911997.
    [Google Scholar]
  12. Sears HF, Herlyn M, Villano D, et al., Monoclonal antibody detection of circulating tumor associated antigen II. Longitudinal evaluation of patients with colorectal carcinoma. J. Clin, Immunol. 1982; 2::141.
    [Google Scholar]
  13. Mineo TC, Ambrogi V, Tonini G, et al., Long-term results after resection of simultaneous and sequential lung and liver metastasis from colorectal carcinoma. American College of Surgery. 2003; 197:3, Sept.
    [Google Scholar]
  14. Kuusela P, Jalanko H, Robert SP, et al., Plasma concentration of tissue inhibitor 1 in patients with colorectal carcinoma. Br J. of Surgery. 2001; 88::15961601.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2007.2.8
Loading

Most Cited Most Cited RSS feed